Kindred Biosciences (NASDAQ:KIN), (ELAN) - Kindred Biosciences Submits Efficacy Data For KIND-030 As Prophylactic Option In US benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
SPAC
Email
Thank You
Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com Start Investing
CureLab Oncology Launches Veterinary Oncology Subsidiary, CureLab Veterinary
Based on a scientifically solid proof of concept in dogs and cats, an international IP portfolio, and a comprehensive scientific advisory board that includes key opinion leaders and experienced management, CureLab Veterinary intends to raise initial financing through a crowdfunding campaign set to launch within a month, and to become profitable within 36 months of raising funds.
News provided by
Share this article
Share this article
BOSTON, Jan. 21, 2021 /PRNewswire/ CureLab Oncology, a clinical-stage pre-IPO biotech company, has launched CureLab Veterinary, a subsidiary with exclusive worldwide rights to apply CureLab Oncology patents to treat dogs, cats and horses. The first target market for CureLab Veterinary s patented DNA therapeutics will be to treat cancer in dogs and cats.
Share this article
Share this article
SAN FRANCISCO, Dec. 22, 2020 /PRNewswire/ Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has initiated the pivotal efficacy study for tirnovetmab (KIND-016), a fully caninized, high-affinity monoclonal antibody targeting interleukin (IL)-31 for the treatment of atopic dermatitis in dogs.
Atopic dermatitis is the most common reason owners take their dog to the veterinarian, and is estimated to affect 10 - 15% of dogs worldwide
1. The current market size is close to $900 million annually and growing. Commencement of the tirnovetmab pivotal study marks an important milestone for KindredBio, said Chief Executive Officer, Richard Chin, M.D. The market for canine atopic dermatitis, allergic dermatitis, and other pruritic diseases already rivals that of many successful human drugs, and continues to experience strong growth. Our market research
Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study for Anti-TNFα Antibody for Canine Inflammatory Bowel Disease
12/21/2020 | 09:32am EDT
Send by mail :
Message :
Required fields
SAN FRANCISCO, Dec. 21, 2020 /PRNewswire/ Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from the pilot field effectiveness study of its monoclonal antibody against tumour necrosis factor alpha (anti-TNFα antibody) for canine inflammatory bowel disease (IBD).
The study was a randomized, blinded, placebo-controlled pilot effectiveness study that enrolled 10 dogs diagnosed with IBD to assess the efficacy and safety of KindredBio s anti-TNFα antibody over a 4-week treatment period. The primary effectiveness variable for this exploratory study was reduction in Canine Inflammatory Bowel Disease Activity Index (CIBDAI) score, which was assessed at Screening and Day